Journal
Article title
Content
Full texts:
Title variants
Treatment with bevacizumab in ovarian cancer – clinical trials review
Languages of publication
Abstracts
Angiogenesis is a process which has been in the focus in the last decade due to its role in the development of cancers. The identification of vascular endothelial growth factor (VEGF) in the beginning of the 80’s became the new objective of therapies of cancers. The finding of angiogenesis inhibitors has brought the therapy of cancers including ovarian cancer in a new era. Apart from the “golden standard” such as the taxans and platinum components, the treatment of ovarian cancer has not introduced any new front-line drugs for many years. The registration of bevacizumab has changed data regarding in particular the progression-free survival (PFS), which was confirmed by GOG-0218 and ICON-7 clinical trials. The aim of the article was to put clinical trials that pointed to the efficiency of bevacizumab in order as well as presenting those whose results may allow in the nearest future for a wider use of bevacizumab – not only in the front-line chemotherapy of ovarian cancer, but also in neoadjuvant therapy and the treatment of a recurrent neoplasm, both platinum-sensitive and platinum-resistant. Studies of predictive factors, which allow for a group of patients who benefit most from anti-angiogenic drugs treatment to be singled out, are also important. At present, clinical trials and scientific studies are under way and maybe they will help identify patients whose PFS and the overall survival (OS) time is be prolonged as a result of treatment with bevacizumab.
Angiogeneza to proces, na którym w ciągu ostatnich dekad skupiono szczególną uwagę, ponieważ odgrywa on istotną rolę w rozwoju nowotworów. Identyfikacja czynnika wzrostu śródbłonka naczyniowego VEGF (vascular endothelial growth factor) na początku lat 80. ubiegłego stulecia stała się niewątpliwie nowym celem terapii nowotworów, a stworzenie leków hamujących angiogenezę umożliwiło wprowadzenie leczenia nowotworów, w tym raka jajnika, w nową erę. Od wielu lat w terapii tego nowotworu, oprócz „złotego standardu”, jakim jest stosowanie taksanów i pochodnych platyny, nie wdrożono nowych leków w pierwszej linii leczenia. Rejestracja bewacizumabu zmieniła dane dotyczące szczególnie czasu wolnego do progresji (progression-free survival, PFS), co potwierdziły badania rejestracyjne tego preparatu (GOG-0218 i ICON-7). Celem pracy było usystematyzowanie badań klinicznych, które dowiodły skuteczności bewacizumabu, a także przedstawienie tych, których wyniki w najbliższej przyszłości mogą pozwolić na szersze zastosowanie leku – nie tylko w terapii pierwszej linii chemioterapii raka jajnika, ale także w terapii neoadiuwantowej oraz w leczeniu wznowy raka jajnika zarówno u pacjentek z nowotworem platynowrażliwym, jak i platynoopornym. Dużej uwagi wymagają też badania nad czynnikami predykcyjnymi, umożliwiającymi wyłonienie grupy pacjentów, którzy mogą uzyskać największą korzyść z leczenia lekami antyangiogennymi. Obecnie trwają badania naukowe i kliniczne, które być może pozwolą zidentyfikować chorych, u których terapia bewacizumabem wydłuży PFS i czas całkowitego przeżycia (overall survival, OS).
Discipline
Journal
Year
Volume
Issue
Pages
286–294
Physical description
Contributors
author
- Klinika Onkologii, Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu. Kierownik: prof. dr hab. n. med. Janina Markowska, jola.lubin@gmail.com
author
- Klinika Perinatologii i Chorób Kobiecych, Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu. Kierownik: prof. dr hab. n. med. Krzysztof Drews
author
- Klinika Onkologii, Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu. Kierownik: prof. dr hab. n. med. Janina Markowska
References
- 1.Folkman J.: What is the evidence that tumors are angiogenesis dependent? J. Natl Cancer Inst. 1990; 82: 4–6.
- 2.Tonini T., Rossi F., Claudio P.P.: Molecular basis of angiogenesis and cancer. Oncogene 2003; 22: 6549–6556.
- 3.Scappaticci F.A.: Mechanism and future directions for angiogenesis-based cancer therapies. J. Clin. Oncol. 2002; 20: 3902–3927.
- 4.Griffioen A.W., Molema G.: Angiogenesis: potentials for pharmacologic in the treatment of cancer, cardiovascular diseases and chronic inflammation. Pharmacol. Rev. 2000; 52: 237–268.
- 5.Senger D.R., Connolly D.T., Van der Water L. i wsp.: Putrification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res. 1990; 50; 1774–1778.
- 6. Mattei M.G., Borg J.P., Rosnet O. i wsp.: Assignment of vascular endothelial growth factor (VEGF) and placenta growth factor (PLGF) genes to human chromosome 6p12- p21 and 14q24-q31 regions respectively. Genomics 1996; 32: 168–169.
- 7. Schmitt J., Matei D.: Targeting angiogenesis in ovarian cancer. Cancer Treat. Rev. 2012; 38: 272–283.
- 8.Adres; www.ema.europa.eu/docs/en_GB/document_library/ Summary_of_opinion/human/000582/WC500112811.pdf.
- 9.Monk B.J., Choi D.C., Pugmire G., Burger R.A.: Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer. Gynecol. Oncol. 2005; 96: 902–905.
- 10.Burger R.A., Brady M.F., Bookman M.A. i wsp.: Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl. J. Med. 2011; 365: 2473–2483.
- 11.Burger R.A., Brady M.F., Bookman A.A. i wsp.: Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): a Gynecologic Oncology Group study. J. Clin. Oncol. 2010; 28: 18, supl. LBA1 ASCO Annual Meeting Proceedings.
- 12.Adres: http://oncofacts.com/archives/gynecologic-cancer-update-from-the-2011-annual-oncology-meeting.
- 13.Perren T.J., Swart A.M., Pfisterer J. i wsp.: A phase 3 trial of bevacizumab in ovarian cancer. N. Engl. J. Med. 2011; 365: 2484–2496.
- 14.Perren T.J., Swart A.M., Pfisterer J. i wsp.; ICON7 Investigators: A phase 3 trial of bevacizumab in ovarian cancer. N. Engl. J. Med. 2011; 365: 2484–2496.
- 15.Oza A.M., Perren T.J., Swart A.M. i wsp.: ICON 7: final overall survival results in the GCIG Phase III randomized trial of bevacizumab in women with newly diagnosed epithelial ovarian cancer. Presented at the European Cancer Congress in Amsterdam, Netherlands, September 27 – October 1, 2013. ECC Oral Presentation.
- 16.Adres: www.clinicaltrials.gov: NCT01706120.
- 17.Adres: www.clinicaltrials.gov.
- 18.Gonzalez-Martin A., Gladieff L., Stroyakovskiy D. i wsp.: Front-line bevacizumab (Bev) combined with weekly paclitaxel (wPAC) and carboplatin (C) for ovarian cancer (OC): safety results from the concurrent chemotherapy (CT) phase of the OCTAVIa study. Eur. J. Cancer 2011; 47: S528.
- 19.Gonzalez-Martin A., Gladief L., Tholander B. i wsp.: Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer. Eur. J. Cancer 2013; 49: 3831–3838.
- 20.Colombo N., Selle F., Korach J. i wsp.: Assessment of safety of surgery in ovarian cancer patients treated with front-line carboplatin, paclitaxel and bevacizumab in the ROSiA routine oncology practice study. Presented at the 18th International Meeting of the European Society of Gynaecological Oncology in Liverpool, UK; October 19–22, 2013. ESGO Oral presentation.
- 21.Adres: www.clinicaltrials.gov: NCT01462890.
- 22.Adres: www.clinicaltrials.gov: NCT00951496.
- 23.Aghajanian C., Blank S.V., Goff B.A. i wsp.: OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J. Clin. Oncol. 2012; 30: 2039–2045.
- 24.Aghajanian C., Finkler N.J., Rutherford T. i wsp.: OCEANS: a phase III multicenter, randomized, blinded, placebo-controlled trial of carboplatin and gemcitabine plus bevacizumab in patients with platinum-sensitive recurrent ovarian, primary peritoneal, or fallopian tube cancer. Presented at the American Society of Clinical Oncology 2011 Annual Meeting in Chicago, IL; June 3-7, 2011. ASCO Oral Presentation #LBA5007.
- 25.Aghajanian C., Nycum L.R., Goff B. i wsp.: Updated overall survival analysis in OCEANS, a randomized phase III trial of gemcitabine (G) + carboplatin (C) and bevacizumab (BV) or placebo (PL) followed by BV or PL in platinum-sensitive recurrent epithelial ovarian (ROC), primary peritoneal (PPC), or fallopian tube cancer (FTC). Ann. Oncol. 2012; 23 supl. 9: ix319.
- 26.Pujade-Laurine E., Hilpert F., Weber B. i wsp.: Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J. Clin. Oncol. 2014 (w druku). DOI: 10.1200/ JCO.2013.51.4489.
- 27.Witteveen P., Lortholary A., Fehm T. i wsp.: Final overall survival results from AURELIA, an open-label randomised phase III trial of chemotherapy with or without bevacizumab for platinum-resistant recurrent ovarian cancer. Presented at the European Cancer Congress in Amsterdam, Netherlands; September 27 – October 1, 2013. ECC Oral presentation.
- 28.Poveda A.M., Selle F., Hilpert F. i wsp.: Weekly paclitaxel (PAC), pegylated liposomal doxorubicin (PLD) or topotecan (TOP) ± bevacizumab (BEV) in platinum (PT)-resistant recurrent ovarian cancer (OC): analysis by chemotherapy (CT) cohort in the GCIG AURELIA randomised phase III trial. Ann. Oncol. 2012; 23 supl. 9: ixe17.
- 29.Adres: www.clinicltrials.gov: NCT00565851.
- 30.Rauh-Hain J.A., Guseh S.H., Esselen K.M. i wsp.: Patterns of recurrence in patients treated with bevacizumab in the primary treatment of advanced epithelial ovarian cancer. Int. J. Gynecol. Cancer 2013; 23: 1219–1225.
- 31.Chéreau E., Lambaudie E., Houvenaeghel G.: Morbidity of surgery after neoadjuwant chemotherapy including bevacizumab for advanced ovarian cancer. Int. J. Gynecol. Cancer 2013; 23: 1326–1330.
- 32.Pujade-Lauraine E.: Bevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancer. J. Gynecol. Oncol. 2013; 24: 209–211.
- 33.Zhao H., Du N., Fu Y. i wsp.: Clinical study of intraperitoneal injection bevacizumab (BV) combined with intraperitoneal hyperthermic perfusion chemotherapy (CT) in treatment of malignant ascites of ovarian cancer (OC). J. Clin. Oncol. 2013; 31 supl. ASCO Annual Meeting Abstracts: abstr. 46F.
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-4a79b416-8e37-4427-ad32-42ea4f2d9a15